Filgotinib (new indication: ulcerative colitis, pretreated patients)

Subject:

• Active Substance: Filgotinib
• Name: Jyseleca^®
• Therapeutic area: Ulcerative colitis
• Pharmaceutical company: Galapagos Biopharma Germany GmbH

Time table:

• Start: 01.12.2021
• Final decision by G-BA: 19.05.2022

Final decision:

• Patients who have responded inadequately to conventional therapy, no longer respond to it, or have an intolerance or contraindication:
  No additional benefit proved
• Patients who have responded inadequately to a biologic (TNF-α antagonist or integrin inhibitor or interleukin inhibitor), no longer respond to it, or have an intolerance to a corresponding treatment:
  No additional benefit proved